Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$1.56 – $2.54
0% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $5.4M | $14.1M | $4.3M | $40.8M | $89.5M | $38.1M | $158.2M |
| Cost of revenue | $4.8M | $5.7M | $6.9M | $8.2M | $2.0M | $4.5M | $11.1M |
| Gross profit | $675.7K | $8.4M | −$2.6M | $32.6M | $87.5M | $33.6M | $147.1M |
| Gross margin | 12.4% | 59.7% | -61.2% | 79.9% | 97.7% | 88.2% | 93.0% |
| R&D | $46.6M | $51.2M | $101.7M | $129.8M | $45.1M | $21.0M | $38.1M |
| Operating income | −$55.7M | −$81.3M | −$142.5M | −$122.2M | $21.8M | −$2.2M | $80.7M |
| EBITDA | −$63.2M | −$290.8M | −$130.8M | −$127.3M | $31.3M | $10.2M | $83.2M |
| Net income | −$67.8M | −$296.5M | −$137.3M | −$137.5M | $22.8M | $2.8M | $91.5M |
| Net margin | -1244.9% | -2101.1% | -3198.2% | -337.5% | 25.5% | 7.3% | 57.8% |
| EPS (diluted) | -0.09 | -0.39 | -0.19 | -0.19 | 0.03 | 0.00 | 0.11 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $230M | $0.09 | $0.08–$0.09 | 1 |
| 2027 | $231M | $0.09 | $0.09–$0.10 | 1 |
| 2028 | $258M | $0.12 | $0.12–$0.13 | 1 |
| 2029 | $200M | $0.00 | $0.00–$0.00 | 0 |
Forward consensus · source: Financial Modeling Prep
HBM HLDGS LTD
No one on the platform currently holds HBMHF.
No tracked institution reports a position in HBMHF as of their last filing.
No one on the platform has traded HBMHF yet.
| $280265 |
| — |
| CINGCingulate Inc. | $5.32 | +7.26% | $30M | — |
| DAWNDay One Biopharmaceuticals, Inc. | $21.53 | +0.00% | $2.2B | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.